1 / 7

Hemophilia A Treatment Market

Hemophilia A patients have begun to shift from short acting to EHL factors and from on demand therapies to prophylactics. The increasing prevalent population of Hemophilia A and the rise in demand of the prophylactics treatments in developed markets will have a great impact on this market.

uday2204
Télécharger la présentation

Hemophilia A Treatment Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hemophilia A Treatment Market Market Size Worth USD 8 Billion By 2022

  2. Hemophilia A Treatment Market Size Worth USD 8 Billion By 2022 “According to Polaris Market Research report, Hemophilia A Treatment is one of the rapidly evolving industry and the global Hemophilia A Treatment Market is estimated to reach USD 8 Billion By 2022 registering a healthy CAGR over the forecast period 2017 to 2022” The global Hemophilia A Treatment Market is driven by certain key factors such as technological innovation in the Hemophilia A Treatment industry, favorable regulatory scenario encouraging market players to develop new products, and efforts by manufacturers to boost the adoption of their offerings. Additionally, industry players are working on business expansion to target untapped markets and managing to deliver their products & services worldwide to augment their revenues. Hemophilia A Treatment Market Report Scope: The research report covers the segmentation of the Hemophilia A Treatment Market based on Standard of Diagnosis, By Approved Drugs, By Care Delivery Model, and region. Analysis of each of the segments projects the snapshot of the market over the forecast years includes the inclination of the market revenue, prevailing patterns, and emerging trends. Increasing consumer awareness regarding products coupled with a rise in disposable income is projected to propel the growth of the Hemophilia A Treatment Marketover the forecast period. - 2 -

  3. Hemophilia A Treatment Market Size Worth USD 8 Billion By 2022 By Standard of By Approved Drugs By Care Delivery By Region Diagnosis Model •Mild Moderate •Afstyla •Prophylaxis •North America (U.S., Canada) •Severe •Eloctate •On-demand therapy •Europe (France, Germany, UK, Italy, Spain, Netherlands, Austria) •Hemlibra •Inhibitor therapy •Kogenate FS •Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea) •Kovaltry •Nuwiq •Latin America (Brazil, Mexico, Argentina) •Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa) Browse Detailed Research Report On Hemophilia A Treatment Market Analysis: https://www.polarismarketresearch.com/industry-analysis/hemophilia-a-treatment- market Regional Outlook North America is anticipated to witness a significant growth rate with major revenue contribution in the Hemophilia A Treatment Market during the forecast period. Major factors influencing the regional market growth include improved infrastructural facilities, positive government initiatives, and the presence of established market players. The Hemophilia A Treatment Market in the Asia Pacific region is projected to grow at a substantial rate over the forecast period. The regional growth is attributed to increasing investments by leading companies to bring innovation inHemophilia A - 3 -

  4. Hemophilia A Treatment Market Size Worth USD 8 Billion By 2022 Treatment industry and attract a large consumer base from leading economies such as India and China. Gain access to our latest research report that includes a detailed analysis of the COVID-19 pandemic influencing the Hemophilia A Treatment Market and how market players devising effective strategies to mitigate the effect of the pandemic: https://www.polarismarketresearch.com/industry-analysis/hemophilia-a-treatment- market/speak-to-analyst Competitive Landscape According to Polaris Market Research, the key players with a considerable market share in the Hemophilia A Treatment Market include (CSL Behring, Shire, Bayer, Biogen, Genentech, Bioverativ, Alnylam Pharmaceuticals, Sanofi (Genzyme), BioMarin Pharmaceutical, Hoffmann- La Roche, Sinocelltech Ltd.).Companies are focusing on R&D activities and strategic collaborations to improve their product portfolio and increase consumer base. Adoption of the latest technologies and product advancement is the key strategy adopted by leading market players. Request for sample: https://www.polarismarketresearch.com/industry-analysis/hemophilia-a- treatment-market/request-for-sample Table of Contents 1. Hemophilia A Treatment Market Summary 2. Hemophilia A Treatment Overview 2.1. Disease Definition 2.2. Hemophilia Types 2.2.1. Mild 2.2.2. Moderate 2.2.3. Severe 2.3. Disease Symptoms 3. Current Diagnosis Patterns 4. Treatment Patterns of Hemophilia A 4.1. Treatment Guidelines for Hemophilia A 5. Hemophilia A treatment Epidemiology -Prevalent Population & Segmentations 5.1. Prevalent Population Globally (2016-2022) 5.1.1. Mild Prevalent Cases (2016-2022) 5.1.2. Moderate Prevalent Cases (2016-2022) 5.1.3. Severe Prevalent Cases (2016-2022) 5.2. Prevalent Population in the United States (2016-2022) 5.2.1. Mild Prevalent Cases (2016-2022) 5.2.2. Moderate Prevalent Cases (2016-2022) 5.2.3. Severe Prevalent Cases (2016-2022) 5.3. Prevalent Population in Germany (2016-2022) - 4 -

  5. Hemophilia A Treatment Market Size Worth USD 8 Billion By 2022 5.3.1. Mild Prevalent Cases (2016-2022) 5.3.2. Moderate Prevalent Cases (2016-2022) 5.3.3. Severe Prevalent Cases (2016-2022) 5.4. Prevalent Population in France (2016-2022) 5.4.1. Mild Prevalent Cases (2016-2022) 5.4.2. Moderate Prevalent Cases (2016-2022) 5.4.3. Severe Prevalent Cases (2016-2022) 5.5. Prevalent Population in Italy (2016-2022) 5.5.1. Mild Prevalent Cases (2016-2022) 5.5.2. Moderate Prevalent Cases (2016-2022) 5.5.3. Severe Prevalent Cases (2016-2022) 5.6. Prevalent Population in Spain (2016-2022) 5.6.1. Mild Prevalent Cases (2016-2022) 5.6.2. Moderate Prevalent Cases (2016-2022) 5.6.3. Severe Prevalent Cases (2016-2022) 5.7. Prevalent Population in United Kingdom (2016-2022) 5.7.1. Mild Prevalent Cases (2016-2022) 5.7.2. Moderate Prevalent Cases (2016-2022) 5.7.3. Severe Prevalent Cases (2016-2022) 5.8. Prevalent Population in Japan (2016-2022) 5.8.1. Mild Prevalent Cases (2016-2022) 5.8.2. Moderate Prevalent Cases (2016-2022) 5.8.3. Severe Prevalent Cases (2016-2022) 6. Current and Future Approaches of Care in Hemophilia A Treatment 6.1. Pre-replacement Therapy 6.2. Replacement Therapy 6.2.1. On Demand 6.2.2. Prophylaxis 6.3. Non-Replacement Therapy 6.3.1. Mimetics/Agonists 6.4. Gene Therapy 7. Marketed Drugs & Sales Forecast in Hemophilia A Treatment 7.1. CSL Behring: Afstyla (Antihemophilic Factor (Recombinant), Single Chain) 7.1.1. Product Profile 7.1.2. Safety & Efficacy 7.1.3. Afstyla Sales Forecast-2016-2022 7.2. Biogen IDEC: Eloctate [Antihemophilic Factor (Recombinant), Fc Fusion Protein] 7.2.1. Product Profile 7.2.2. Safety & Efficacy 7.2.3. Eloctate Sales Forecast-2016-2022 7.3. Genentech: Hemlibra (emicizumab-kxwh) 7.3.1. Product Profile 7.3.2. Safety & Efficacy 7.3.3. Hemlibra Sales Forecast-2016-2022 7.4. Bayer: Kogenate FS (Antihemophilic Factor Recombinant) 7.4.1. Product Profile 7.4.2. Safety & Efficacy 7.4.3. Kogenate FS Sales Forecast-2016-2022 7.5. Bayer: Kovaltry [Antihemophilic Factor (Recombinant) 7.5.1. Product Profile 7.5.2. Safety & Efficacy 7.5.3. Kovaltry Sales Forecast-2016-2022 - 5 -

  6. Hemophilia A Treatment Market Size Worth USD 8 Billion By 2022 7.6. Octapharma: Nuwiq (recombinant Factor VIII) 7.6.1. Product Profile 7.6.2. Safety & Efficacy 7.6.3. Nuwiq Sales Forecast-2016-2022 7.7. Shire (Baxter): Obizur [Antihemophilic Factor (Recombinant), Porcine Sequence] 7.7.1. Product Profile 7.7.2. Safety & Efficacy 7.7.3. Obizur Sales Forecast-2016-2022 8. Market Size & Forecast of Hemophilia A Treatment(2016-2022) 8.1. Market Forecast by Disease Care 8.1.1. Prophylaxis-Market Forecast (2016-2022) 8.1.2. On-demand therapy-Market Forecast (2016-2022) 8.1.3. Inhibitor therapy- Market Forecast (2016-2022) 8.2. Market Forecast by G7 Countries (2016-2022) 8.2.1. United States- Market Forecast (2016-2022) 8.2.2. Germany- Market Forecast (2016-2022) 8.2.3. France-Market Forecast (2016-2022) 8.2.4. Italy- Market Forecast (2016-2022) 8.2.5. Spain- Market Forecast (2016-2022) 8.2.6. United Kingdom- Market Forecast (2016-2022) 8.2.7. Japan- Market Forecast (2016-2022) 9. Factors Driving the Market of Hemophilia A Treatment 10. Factors Restraining the Market of Hemophilia A Treatment 11. About Polaris Market Research 12. Disclaimer 13. Sales Support Access Press Release on Hemophilia A Treatment Market : https://www.polarismarketresearch.com/press-releases/global-hemophilia-a-treatment- market About Polaris Market Research Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to our customers. E mail Id: sales@polarismarketresearch.com - 6 -

  7. Hemophilia A Treatment Market Size Worth USD 8 Billion By 2022 Web: www.polarismarketresearch.com Official Blog: http://polarismarketresearch.blogspot.com - 7 -

More Related